Table of Contents
Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two most studied cannabinoids from the cannabis plant, but they differ sharply in effects, legal status, and suitability for Indian consumers. In India, CBD-dominant, leaf-derived or hemp-compliant products are increasingly available under AYUSH/FSSAI frameworks, while high-THC “ganja/charas” remains prohibited under the NDPS Act, with only narrow exceptions for bhang and licensed medical use.
CBD and THC in India: Why the Difference Matters Here
India’s cannabis law hinges on plant part and THC content, not just the molecule name. The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 defines “cannabis (hemp)” as charas, ganja, and mixtures, but expressly excludes seeds and leaves. This means leaf-derived CBD sold under an Ayurvedic/AYUSH licence can fall outside the NDPS “cannabis” definition, whereas flowering-top or resin-derived CBD/THC is controlled. At the same time, industrial hemp cultivation is permitted in some states, and FSSAI sets ceilings for hemp-seed foods. Practically, compliant CBD products are far more accessible than THC-dominant options for most Indian users.
What Is CBD (Cannabidiol)?
CBD is a non-intoxicating phytocannabinoid that does not produce a “high.” Pharmacologically, CBD has a multimodal profile: it acts as a negative allosteric modulator at CB1, shows CB2 inverse agonism/antagonism, inhibits anandamide inactivation, and engages 5-HT1A, TRP channels, GPR55, and PPAR-γ. Clinically, the strongest evidence supports purified CBD for certain epilepsies (e.g., Dravet, Lennox–Gastaut), with smaller trials suggesting anxiolytic effects at intermediate oral doses in an inverted-U dose–response. In India, CBD is commonly marketed as oils, tinctures, topicals, and gummies under AYUSH or as hemp-derived supplements, provided they meet THC thresholds and licensing norms.
What Is THC (Tetrahydrocannabinol)?
THC is the primary psychoactive cannabinoid in cannabis, acting mainly as a partial agonist at CB1 and CB2 receptors to produce euphoria, appetite stimulation, antiemetic, and analgesic effects. However, THC can be anxiogenic—especially at higher doses or in inexperienced users—and chronic high-potency use is associated with increased anxiety and cognitive/psychiatric risks. In India, recreational THC (ganja/charas) is prohibited nationwide under the NDPS Act; limited legal pathways exist for bhang (leaf preparations) in some states and for licensed medical products, but high-THC retail remains restricted.
CBD vs THC: Head-to-Head Comparison
| Feature | CBD (Cannabidiol) | THC (Tetrahydrocannabinol) |
| Psychoactive (“high”) | No | Yes |
| Primary receptors | CB1 negative allosteric modulator; CB2 inverse agonist/antagonist; 5-HT1A, TRP, GPR55, PPAR-γ | CB1/CB2 partial agonist |
| Anxiety effects | Anxiolytic in small RCTs; inverted-U dose response | Can increase anxiety, especially at high doses |
| Pain relief | Modest evidence; better for inflammatory/neuropathic components in some contexts | Slight benefit for chronic/neuropathic pain in reviews; stronger for some pain subtypes |
| Legal status in India | Leaf-derived/AYUSH or hemp ; flower/resin-derived is controlled | Ganja/charas prohibited; bhang (leaf) exempt in some states; medical access limited/licensed |
| Drug testing | Unlikely to trigger standard THC screens | Likely to trigger THC urine/blood tests |
| Common Indian formats | Oils, tinctures, topicals, gummies, capsules (AYUSH/hemp) | Mostly illicit flower/resin; limited licensed medical products |
CBD vs THC for Specific Conditions in India
- Anxiety: CBD-dominant products are associated with more consistent anxiety reductions over time, while THC alone can worsen anxiety in some users. A 30-day naturalistic study found CBD and THC+CBD flower outperformed THC-only for anxiety reduction; CBD edibles also showed sustained benefits. For Indian users prioritizing anxiety relief without intoxication, CBD-first strategies are typically safer.
- Chronic/neuropathic pain: Reviews suggest higher-THC products may slightly reduce chronic nerve pain, but benefits are modest and risk–benefit must be weighed. CBD may help inflammatory components and is better tolerated long term for many.
- Sleep/insomnia: Evidence for cannabinoids in insomnia remains insufficient or mixed; some patients report symptom relief with full-spectrum extracts, but robust trials are limited.
- Nausea/appetite: THC-based agents have established antiemetic and appetite-stimulating effects in specific indications (e.g., chemotherapy nausea), whereas CBD is not a primary antiemetic.
What About Full Spectrum — CBD and THC Together?
Full-spectrum extracts contain CBD, trace THC and other cannabinoids/terpenes. Prospective data suggest full-spectrum cannabis extracts can act as adjuvants for chronic pain, with many patients reporting ≥50% reductions in pain, anxiety, and insomnia over time. In anxiety, combinations (THC+CBD) sometimes outperform THC alone, but CBD-dominant regimens still show the most consistent anxiolytic signal. In India, choose FSSAI/AYUSH-compliant full-spectrum products with verified THC to stay within regulatory guardrails.
Will THC Show on a Drug Test in India?
Standard workplace or forensic drug tests in India typically screen for THC metabolites, not CBD. Using THC-containing products (including some full-spectrum CBD with measurable THC) can trigger a positive result, whereas CBD isolate or verified THC-free products are unlikely to do so. If you face testing, prioritize products with third-party certificates showing non-detectable THC.
How to Choose Between CBD and THC Products at Cannazo India
When browsing Cannazo India or similar retailers, use this checklist:
- Goal: Anxiety, daytime function, or sensitivity to intoxication → lean CBD or CBD-dominant full spectrum.
- THC content: Verify lab reports; for legal compliance and lower test risk, choose low THC or THC-free.
- Spectrum: Isolate (CBD only) for zero-THC needs; broad/full spectrum for potential synergy if THC trace is acceptable.
- Dose form: Oils/tinctures for titration; gummies/capsules for convenience; topicals for localized pain.
- Compliance: Prefer AYUSH-licensed or FSSAI-compliant brands with batch COAs.
Conclusion
For most Indian consumers, CBD offers a non-intoxicating, legally clearer path for anxiety, mild-to-moderate pain, and daily wellness, while THC remains restricted and better reserved for specific medical indications under supervision. If you consider THC, ensure medical guidance, legal compliance, and awareness of drug-testing implications.
FAQ
-
What is the main difference between CBD and THC in India?
CBD is non-intoxicating and often legally available as leaf-derived/AYUSH or hemp-compliant products; THC is psychoactive and largely prohibited as ganja/charas under the NDPS Act, with limited exceptions. -
Is THC legal in India?
Recreational THC (ganja/charas) is prohibited nationwide; bhang (leaf preparations) is exempt in some states, and licensed medical pathways exist but are narrow. -
Should I take CBD or THC for anxiety in India?
CBD is generally preferred for anxiety due to anxiolytic signals and lower risk of worsening anxiety; THC can be anxiogenic, especially at higher doses. -
Does CBD get you high in India?
No. CBD does not produce a psychoactive “high.” -
Which is better for pain relief, CBD or THC?
For chronic/neuropathic pain, higher-THC products may offer slight benefits, but evidence is modest; CBD may help inflammatory components and is better tolerated for many users.
References
- Cannintel. (2026, August 28). India faces regulatory gap as semi-synthetic cannabinoids evade NDPS Act. https://cannintel.com/laws/india-semi-synthetic-cannabinoids-regulatory-gap-ndps-act
- Cannintel. (2026, July 26). India cannabis laws: NDPS Act, bhang exemptions & state variations. https://cannintel.com/topics/india-cannabis-laws
- CrescentCanna. (2026, April 4). Is weed legal in India 2026? NDPS Act guide. https://www.crescentcanna.in/blogs/blog-posts/is-weed-legal-in-india-2026
- Kushiva. (2026, July 27). Is cannabis legal in India? NDPS Act, bhang & Vijaya (2026). https://www.kushiva.com/blog/kushiva-journal-2/is-cannabis-legal-in-india-21
- MDPI. (2026, February 10). Therapeutically motivated cannabis use for anxiety: Daily and longitudinal reductions vary between flower and edible products. International Journal of Environmental Research and Public Health, 23(2), 224. https://www.mdpi.com/1660-4601/23/2/224
- MDPI. (2026, July 24). Neuropharmacology of cannabinoids: A comprehensive review of preclinical and clinical evidence for hemp-derived extracts and active compounds.
- Pharmaceuticals, 19(8), 1151. https://www.mdpi.com/1424-8247/19/8/1151
ScienceDaily. (2026, August 31). Marijuana news. https://www.sciencedaily.com/news/mind_brain/marijuana/ - SecondOpinionFromAI. (2026, August 3). What are the current CBD extraction regulations in India for 2026? https://secondopinionfromai.com/knowledge/what_are_the_current_cbd_extraction_regulations_in_india_for_2026.php
- Trapothecary. (2026, June 17). Is CBD legal in India? 2024 cannabinoid guide. https://trapothecary.com/international/india/
- 2CB.com. (2026, July 14). Is CBD legal in India? https://2cb.com/legality/cbd/india
- CannabisRegulations.ai. (2026, August 7). Is hemp legal in India? 2026 FSSAI and state licensing. https://www.cannabisregulations.ai/country-legality/india-hemp
- Herb.co. (2026, February 25). Cannabis laws, bhang & what tourists should know in Goa. https://herb.co/city-guides/buy-weed-india
- Tandfonline. (2025, July 3). Effectiveness of full spectrum cannabis extracts in the treatment of chronic pain. https://www.tandfonline.com/doi/full/10.1080/15360288.2025.2517778
- Wiley. (2026, May 1). Higher THC concentration medicinal cannabis products. Drug and Alcohol Review. https://onlinelibrary.wiley.com/doi/full/10.1111/dar.70145
- Gavin Publishers. (2025, July 24). The therapeutic potential of major cannabinoids in the management of anxiety disorders. https://www.gavinpublishers.com/article/view/the-therapeutic-potential-of-major-cannabinoids-in-the-management-of-anxiety-disorders-rediscovering-psychopharmacology
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of Cannazo India.